Review explores cutaneous manifestations of myelodysplastic syndrome
Cutaneous manifestations of myelodysplastic syndrome (MDS) are described in a perspective piece published in the April issue of Skin Health and Disease.
20 hours ago
0
0
Cutaneous manifestations of myelodysplastic syndrome (MDS) are described in a perspective piece published in the April issue of Skin Health and Disease.
20 hours ago
0
0
A new research paper titled "Exploring the role of GHRH antagonist MIA-602 in overcoming Doxorubicin-resistance in acute myeloid leukemia" has been published in Oncotarget.
Apr 10, 2024
0
0
Researchers at the University of Zurich and the University Hospital Zurich have discovered that a specific mutation in the cancer cells of an aggressive type of blood cancer can prevent novel immunotherapies such as CAR T-cell ...
Mar 21, 2024
0
23
In a recently published review in the journal Biomarker Research, Joanna Zawacka, Docent at the department of Oncology-Pathology discusses our current understanding of p53 biology in myelodysplastic syndrome (MDS) and acute ...
Mar 20, 2024
0
0
National University of Singapore (NUS) scientists have discovered that the evasion of apoptosis is a key driver of drug resistance in patients with relapsed acute myeloid leukemia (AML), a type of aggressive blood cancer. ...
Mar 19, 2024
0
0
Scientists at City of Hope, one of the largest cancer research and treatment organizations in the United States, have devised an innovative approach to target and destroy hard-to-kill leukemia stem cells. The journal Blood ...
Feb 26, 2024
0
31
A genetic test that identifies cancer mutations in solid tumors and that was developed by researchers at Washington University School of Medicine in St. Louis has been approved for reimbursement by the Centers for Medicare ...
Feb 26, 2024
0
1
For adults with acute myeloid leukemia (AML), those with central nervous system (CNS) involvement have worse overall survival, according to a review published in the February issue of Leukemia Research.
Feb 21, 2024
0
0
Scientists at The University of Texas at Austin have discovered how an aggressive and deadly form of leukemia fuels its growth. In an experimental study, they were able to curb the cancer's growth without harming healthy ...
Feb 14, 2024
0
126
St. Jude Children's Research Hospital scientists have improved chimeric antigen receptor (CAR) T–cell immunotherapy for acute myeloid leukemia (AML), demonstrating better efficacy in the lab.
Feb 12, 2024
0
24
Acute myeloid leukemia (AML), also known as acute myelogenous leukemia, is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. AML is the most common acute leukemia affecting adults, and its incidence increases with age. Although AML is a relatively rare disease, accounting for approximately 1.2% of cancer deaths in the United States, its incidence is expected to increase as the population ages.
The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells. These symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. Although several risk factors for AML have been identified, the specific cause of the disease remains unclear. As an acute leukemia, AML progresses rapidly and is typically fatal within weeks or months if left untreated.
AML has several subtypes; treatment and prognosis varies among subtypes. 5-year survival varies from 15-70%, and relapse rate varies from 78-33%, depending on subtype. AML is treated initially with chemotherapy aimed at inducing a remission; patients may go on to receive additional chemotherapy or a hematopoietic stem cell transplant. Recent research into the genetics of AML has developed tests that better predict how long a patient is likely to survive and whether a drug is likely to be effective.
This text uses material from Wikipedia, licensed under CC BY-SA